Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Eton Pharmaceutcials, Inc. Common Stock

ETON

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.

Last trade $63.52
Day change -$0.36 (-0.56%)
Day range $62.16 – $64.64
Volume 266,927
Market cap $1.84B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.84B
Price / earnings
36.95×
Price / book
21.2×
Price / sales
13.06×
EV / sales
12.83×
EV / EBITDA
39.64×

Profitability

Earnings per share
$1.73
Return on assets
31.71%
Return on equity
57.37%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.27×
Current ratio
1.79×
Quick ratio
1.58×
Cash ratio
1.03×

Cash flow

Price / cash flow
48.04×
Price / free cash flow
48.21×
Free cash flow
$38.22M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ETON, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$57.93M$37.59M$24.27M$21.28M$22.46M$18.93M$17.28M$11.65M
Cost of revenue$13.62M$12.18M$9.53M$8.18M$14.6M$7M$7.42M$5.17M
Gross profit$44.3M$25.41M$14.74M$13.1M$7.86M$11.92M$9.86M$6.48M
Selling, general and administrative$16.02M$11.63M$10.45M$8.86M$8.11M$9.69M$9.17M$6.72M
Research and development$5.27M$993K$1.88M$1.78M$1.11M$3.71M$1.16M-$871K
Total operating expenses$21.29M$12.62M$12.32M$10.64M$9.22M$13.4M$10.33M$5.85M
Operating income$23.01M$12.79M$2.41M$2.46M-$1.36M-$1.48M-$470K$629K
Interest expense-$656K-$1.08M$0$0-$592K-$1.04M$0$0
Income before taxes$22.36M$11.72M$1.57M$1.41M-$1.96M-$2.52M-$1.5M-$511K
Income taxes-$12.89M$140K$20K-$69K-$28K$66K$74K$87K
Net income$35.25M$11.58M$1.55M$1.48M-$1.93M-$2.59M-$1.57M-$598K
Net income attributable to common shareholders$35.25M$11.58M$1.55M$1.48M-$1.93M-$2.59M-$1.57M-$598K
EBITDA$24.46M$14.18M$3.55M$3.48M-$354K-$470K$543K$984K
Basic earnings per share$1.23$0.42$0.06$0.06-$0.07-$0.10-$0.06-$0.02
Diluted earnings per share$1.06$0.35$0.05$0.06-$0.07-$0.10-$0.06-$0.02

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Eton Q3 Earnings Call Highlights Growth and Pipeline Expansion

Eton Pharmaceuticals exceeded expectations in Q3 2026 with revenues of $57.9M (158% YoY growth) and raised full-year revenue guidance to over $175M with adjusted EBITDA margins above 40%. The company achieved its $200M annualized revenue run-rate target five quarters ahead of schedule, driven primarily by HEMANGEOL sales. Eton is preparing for an April 2027 LIBERVANT launch and advancing its pipeline including ASN-001 and ET-900.

Zacks Investment Research

Eton Pharmaceuticals, Inc. (ETON) Q3 Earnings and Revenues Surpass Estimates

Eton Pharmaceuticals reported Q3 2026 earnings of $1.06 per share, significantly beating the consensus estimate of $0.34 per share, representing a 211.77% earnings surprise. Revenues reached $57.93 million, surpassing estimates by 37.23% compared to $22.46 million year-ago. The stock has gained 199.9% year-to-date. However, the company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

ETON Gears Up to Report Q3 Earnings: What Can Investors Expect?

Eton Pharmaceuticals is set to report Q3 2026 earnings on Nov. 5, 2026, with consensus revenue estimates of $42.2 million and EPS of 34 cents. Growth is expected from commercial products like Increlex, Alkindi Sprinkle, and Galzin, while recent launches including Impavido and the planned Libervant launch could provide additional revenue opportunities. However, higher R&D spending may pressure operating margins. The company has a mixed earnings surprise history and an Earnings ESP of 0.00%, suggesting no conclusive beat prediction.

Zacks Investment Research

ETON Stock Surges 108% in Six Months: Here's What You Need to Know

Eton Pharmaceuticals has gained 108% over six months, driven by 99% Q2 product sales growth and successful Hemangeol relaunch. The company raised 2026 revenue guidance to above $145 million with 35%+ adjusted EBITDA margins. Pipeline expansion including new launches and late-stage candidates like ASN-001 provide additional growth opportunities.

GlobeNewswire Inc.

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

Eton Pharmaceuticals announced record Q2 2026 revenue with product sales of $37.6 million, representing 99% year-over-year growth. The company reported GAAP EPS of $0.35 and non-GAAP EPS of $0.43, with EBITDA of $14.1 million. Additionally, Eton expanded its infantile hemangioma franchise by acquiring U.S. rights to ASN-001, a late-stage product candidate targeting moderate infantile hemangiomas, complementing its existing HEMANGEOL product.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.